Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$17.43 USD

17.43
643,813

-0.42 (-2.35%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $17.43 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Buy Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

Zacks Equity Research

UnitedHealth's (UNH) Optum to Boost Northern Light's Efficiency

by Zacks Equity Research

Per the deal, around 1,400 employees of Northern Light are likely to shift to UnitedHealth's (UNH) Optum this March.

Zacks Equity Research

Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.

Zacks Equity Research

Alcon (ALC) Gains From Innovation, Faces FX Challenges

by Zacks Equity Research

Alcon's (ALC) Surgical franchise continues to lead the market with its portfolio of advanced technology, intraocular lenses, a substantial installed base of equipment and a growing consumable base.

Zacks Equity Research

AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.

Zacks Equity Research

Here's Why You Should Retain Ecolab (ECL) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

Zacks Equity Research

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio (Revised)

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Zacks Equity Research

Bruker's (BRKR) New Tie-Up to Expand Its U.S. CRO Business

by Zacks Equity Research

Bruker's (BRKR) latest partnership is expected to expand its CRO business in the United States, benefiting more biopharma and diagnostics companies using unbiased proteomics for decision-making.

Zacks Equity Research

Here's Why You Should Retain Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.

Zacks Equity Research

Walgreens Boots (WBA) Q1 Earnings Top, Revenues View Up

by Zacks Equity Research

The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.

Zacks Equity Research

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Zacks Equity Research

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.

Zacks Equity Research

HCA Healthcare (HCA) Unit in Talks to Buy Wise Health System

by Zacks Equity Research

HCA Healthcare's (HCA) deal with Wise Health System is expected to boost its footprint and market share in Texas.

Zacks Equity Research

AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed the most recent trading day at $103.97, moving -1.92% from the previous trading session.

Zacks Equity Research

Masimo's (MASI) SpHb During Elective CS Favored by New Study

by Zacks Equity Research

Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.

Zacks Equity Research

Here's Why You Should Retain PacBio (PACB) Stock for Now

by Zacks Equity Research

PacBio's (PACB) strength in its Sequel system raises optimism about the stock.

Zacks Equity Research

Walgreens (WBA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Walgreens' (WBA) strategic executions on both the United States and the international front are likely to have contributed to the Q1 2023 top line.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.

Zacks Equity Research

Are Medical Stocks Lagging AMN Healthcare Services (AMN) This Year?

by Zacks Equity Research

Here is how AMN Healthcare Services (AMN) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

Zacks Equity Research

Molina's (MOH) California Medicaid Revenues to Double in 2024

by Zacks Equity Research

Molina Healthcare (MOH) expects combined revenues from California, Nebraska, and Iowa in 2024 to reach $4.2 billion.

Zacks Equity Research

Why Hold Strategy is Apt for Centene (CNC) Stock Right Now

by Zacks Equity Research

Centene's (CNC) health benefits ratio is expected to improve in the coming days, signaling better operating efficiency.

Zacks Equity Research

AMN or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Zacks Equity Research

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $103 in the latest trading session, marking a +0.2% move from the prior day.

Zacks Equity Research

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, AMN Healthcare Services (AMN) closed at $103.46, marking a +0.46% move from the previous day.